Argenica Therapeutics (AGN) AGM 2024 presentation summary

Mission and vision

• Aims to commercialize a neuroprotective treatment minimizing brain damage and fostering recovery after stroke and other neurological conditions.

• Seeks to redefine the standard of care for stroke and neurological conditions by reducing brain injury.

• ARG-007, a cationic poly-arginine peptide, has multiple mechanisms of action and strong intellectual property.

• Over 25 peer-reviewed papers support the safety and efficacy of ARG-007 in healthy humans.

2024 achievements and clinical progress

• Commenced Phase 2 clinical trial in acute ischaemic stroke (AIS) patients, dosing 63% of target patients.

• No serious adverse events related to drug administration in the first 50% of patients dosed.

• Positive IND-enabling studies for stroke and significant efficacy in large animal models of traumatic brain injury.

• FDA granted Rare Pediatric Disease and Orphan Drug Designations for ARG-007 and ARG-006 in HIE.

• Significant board and management appointments made.

Lead drug candidate and indications

• ARG-007 targets stroke, severe and mild/moderate traumatic brain injury (TBI), hypoxic ischemic encephalopathy (HIE), and Alzheimer's disease.

• Single dose of ARG-007 in severe TBI can move directly from preclinical to Phase 2 clinical trial.